Immuneering Corporation (IMRX )

Currency in USD Disclaimer
$3.76 +$0.72 (23.68%)
Closed 08/15/2025
$3
$3.81
$1
$4.69

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol IMRX
  • Company Immuneering Corporation
  • Price $3.76
  • Changes Percentage 23.68
  • Change 0.72
  • Day Low $3
  • Day High $3.81
  • Year High $4.69
  • Year Low $1
  • Market Cap $116,953,525
  • Price Avg 50 EMA (D) $3.17
  • Price Avg 200 EMA (D) $2.12
  • Exchange NASDAQ
  • Volume 346,859
  • Average Volume 1,270,185
  • Open $3
  • Previous Close $3.04
  • EPS -1.97
  • PE -1.65
  • Earnings Announcement 2025-08-11 20:00:00
  • Shares Outstanding $35,985,700

Company brief: IMMUNEERING CORPORATION (IMRX )

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

IMRX Corporation News

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 13, 2025 at 8:05 pm ET

globenewswire.com -- - Company now plans to share updated OS and PFS data from first-line pancreatic cancer patients (N = 34) treated with atebimetinib + mGnP in Q3 2025, earlier than prior guidance - - Exceptional 94% o...

Income Statement